Sort
82,697 grants matching “vaccine development”
Nonhuman primate scientific research support component
$1,249,558Sampa Santra · Duke University · UM1 · FY2017 · AI
Development of Novel Immunogens for Vaccines to HIV-1
$1,249,490Maxygen, Inc. · P01 · FY2005 · AI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population
$1,249,406Beth Diane Kirkpatrick · University Of Vermont & St Agric College · U01 · FY2023 · AI
Seasonal Influenza Vaccine Effectiveness in a Tropical Developing African Country
$1,249,339John Christian Victor · Path · U01 · FY2011 · IP
Cellular and Developmental Biology of Coxiella burnetii
$1,249,247Robert A Heinzen · Niaid Extramural Activities · Z01 · FY2007 · AI
Multiscale Analysis of Immune Responses
$1,248,975Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder
$1,248,915Misty Ward Stevens · Intervexion Therapeutics, Llc · U01 · FY2022 · DA
Genes for Tolerance and Immunity Consortium
$1,248,749Australian National University · R01 · FY2005 · AI
Discovery of new cellular targets for small-molecule inhibition of enveloped vir
$1,248,634Sean P. J. Whelan · Harvard Medical School · U19 · FY2017 · AI
LOS ANGELES PEDIATRIC AIDS CONSORTIUM
$1,248,584University Of California Los Angeles · U01 · FY2000 · AI
GENETIC APPROACHES FOR CANCER IMMUNOTHERAPY
$1,248,539University Of Michigan At Ann Arbor · P01 · FY2000 · CA
Development of a novel adjuvant for vaccine sparing
$1,248,398Sara Lustigman · New York Blood Center · R01 · FY2017 · AI
Development of a Yellow Fever Vaccine for a Vulnerable Population
$1,248,114Ian James Amanna · Najit Technologies, Inc. · R44 · FY2018 · AI
Innate inflammatory responses during pulmonary infections
$1,247,742Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Monetary incentives and intrinsic motivation to sustain hypertension control
$1,247,695Martin F Shapiro · University Of California Los Angeles · RC4 · FY2010 · AG
SBIR Phase II: Dense Nanolipid Fluids (DNLFs) for Delivery of Drugs with Poor Bioavailability: Synthesis, Manufacture, and Drug Properties
$1,247,672Eric D Morrison · Superior Nano Llc · · FY2025 · TIP
Cardiac Transplantation in Infancy
$1,247,290Mayo Clinic · P01 · FY2005 · HL
Genes for Tolerance and Immunity Consortium
$1,247,125Christopher C Goodnow · Australian National University · R01 · FY2006 · AI
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
$1,247,121S Munir Alam · Duke University · P01 · FY2019 · AI
Immune Function and Biodefense in Immunocrompromised Populations
$1,246,937Erol Fikrig · Yale University · N01 · FY2010 · AI
UNC CENTER FOR AIDS RESEARCH
$1,246,922University Of North Carolina Chapel Hill · P30 · FY2000 · HD
Towards a predictive understanding of influenza immunity through experimental data integration, iterative model development, and rigorous assessment of model quality
$1,246,617Bjoern Peters · La Jolla Institute For Immunology · U01 · FY2025 · AI
Regulation Of Immunopathology In Bacterial And Parasitic Disease
$1,246,356Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms
$1,246,317Michael W Cho · Iowa State University · U19 · FY2011 · AI
Antiviral therapeutics for flavivirus infections
$1,246,033Dennis E. Hruby · Siga Technologies, Inc. · R01 · FY2014 · AI